Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets falter for third day
Wed, 11 Mar 03:30 pm

Indian markets showed positive movements on the back of encouraging developments in the European market, however pared gains later on. The European Commission Board stated that the bond purchase program has started. BSE-Sensex is trading down by 0.2% or 60 points while NSE-Nifty is trading in the red by 0.2% or 20 points. Marginal gains are witnessed in information technology, banks and FMCG, however, metals continue to remain the highest loser.

S&P BSE Midcap and S&P BSE Smallcap underperformed today's market performance as they continued to trade in the negative. Midcap stocks are trading in the red with 0.4% losses while smallcap stocks are trading with 0.3% losses. Commodities are trading flattish. Gold prices per 10 grams, declined 0.1% or Rs 5 to Rs 25,900 levels, while Silver prices, per kilogram increased 0.1% to Rs 35,745. Crude oil prices, per barrel, have increased marginally to Rs 3,062.

European markets received a major boost as ECB announced that it has started the bond purchase program. This instantly provided the positive catalyst the market was looking for. All the European markets, DAX, CAC and FTSE have gained over 1% in today's trading session. However, scepticism over Greece's bailout remains on shore.

Power companies were the biggest beneficiaries of the coal auction. Shares of CESC jumped over 5% after the West Bengal Electricity Regulatory Commission approved a tariff plan at the rate of Rs 6.98 per unit. The pricing will benefit in a way that experts can value the company's two years earnings based on this price. According to leading financial sources, CESC might face a positive re-rating which would make investor sentiment optimistic.

Healthcare sector faced selling pressure with heavyweight companies such as Lupin and Sun Pharma falling over 1%. However, Shilpa Medicare gained over 10% as it awaits approval for two of its sites by US Food and Drug Administration. Both the sites are located at Raichur. The company has had approval from European countries, Japan and Mexico for the largest API facility of oncology in India. It now awaits US FDA approval for these two facilities. The auditors had come last week for inspection.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets falter for third day". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.